Literature DB >> 1703227

Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.

P J Hoskins1, V Ng, J J Spinelli, P Klimo, J M Connors.   

Abstract

One hundred twenty-six patients with diffuse large-cell lymphoma were treated with methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) between April 1981 and June 1986. Univariate and multivariate analyses were performed using overall survival as of September 1989 as the end point. Four independent negative predictors of survival were identified: presence of B symptoms; more than two involved lymph node sites; more than one extranodal site (variables related to tumor burden), and age older than 60, a variable related to the patient's ability to tolerate treatment. Each variable contributed the same relative risk of dying and, accordingly, this simple predictive formula was developed empirically: (4-N) x 30 = the approximate percentage of chance of survival at 5 years. "N" is the number of predictive variables present. The same four predictors were also found to be significant by multivariate analysis when only those patients achieving a complete response were analyzed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703227     DOI: 10.1200/JCO.1991.9.2.220

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

Review 1.  Non-Hodgkin's lymphoma. I: Characterisation and treatment.

Authors:  S E O'Reilly; J M Connors
Journal:  BMJ       Date:  1992-06-27

2.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

3.  Prognostic significance of biochemical markers in African Burkitt's lymphoma.

Authors:  F K N Arthur; L Owusu; F A Yeboah; T Rettig; A Osei-Akoto
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

4.  Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass.

Authors:  Hirotaka Takasaki; Wataru Yamamoto; Yoshimi Ishii; Hiroyuki Takahashi; Reina Watanabe; Taishi Harada; Rika Kawasaki; Chizuko Hashimoto; Shigeki Motomura; Naoto Tomita; Yoshiaki Ishigatsubo; Rika Sakai
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-03       Impact factor: 0.900

Review 5.  Combined chemotherapy plus radiotherapy for treatment of early-stage intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  J H Briggs; T P Miller
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

6.  Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.

Authors:  H S Dhaliwal; A Z Rohatiner; W Gregory; M A Richards; P W Johnson; J S Whelan; C J Gallagher; J Matthews; T S Ganesan; M J Barnett
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.